- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02023047
An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing
November 15, 2015 updated by: RDD Pharma Ltd
This is an open label study.
The study will consist of 2 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2).
Approximately 30 subjects will participate into this 8-week study.
The primary objective is to examine the dose effect of coated Nifedipine suppository on Anal fissure pain and healing.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
This is an open label study.
The study will consist of 2 treatment group: coated Nifedipine suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2).
Approximately 30 subjects will participate into this 8-week study.
A screening visit will be used to determine subject suitability for inclusion in the trial.
Within one week of the screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria will receive Coated Nifedipine 12 mg Suppository X2 a day (BID) (24 mg/day total) OR Coated Nifedipine 12 mg Suppository X1 a day (OD) (12 mg/day total) for a period of 8 weeks.
During this period, 4 study visits (at 0, 2, 5, and 8 weeks) will take place.
Study medication will be administered BID (in the morning and in the evening) or OD (only in the morning).
In addition to receiving study medication, subjects will be maintained on a standard treatment for Anal Fissure: sitz baths, high fiber diet.
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Rehovot, Israel
- Macabi outpatient clinic
-
Tel Aviv, Israel
- Macabi HMO outpatient clinic
-
Zrifin, Israel
- Asaf Harofe Hospital
-
-
Negev
-
Beer Sheba, Negev, Israel
- Macabi outpatient clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Single anal fissure
- Signed written informed consent;
- Male or female subjects 18 to 65 years of age;
- Has chronic anal fissure defined as history of anal pain at least three days a week for 30 days duration or more
- Visible fibers of the internal sphincter were seen at the base of the fissure or if a sentinel pile was present.
- VAS of > 35 mm in screening visit
- If female, is non-lactating, has a negative urine pregnancy test result, and does not plan on becoming pregnant during the study, or not of childbearing potential (hysterectomy or tubal ligation at least 6 months prior to entry to the study or post-menopausal for 1 year); if of childbearing potential (including peri-menopausal women who have had a menstrual period within one year) must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration.
Exclusion Criteria:
- Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone.
- Fissure resulting from inflammatory bowel disease, venereal disease, perianal psoriasis, immunodeficiency syndrome.
- Anal abscess
- Fixed anal stenosis
- Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, moderate to severe congestive heart failure, or cardiac valve abnormalities;
- Type 1 diabetes mellitus;
- Insulin treated type 2 diabetes mellitus;
- History of Renal insufficiency.
- History of Liver insufficiency.
- Malignant disease within 5 years of screening;
- Has uncontrolled hypertension (sitting blood pressure <160/95 mmHg at screening)
- History of chronic gastrointestinal disease.
- History of rectal surgery.
- History of gastrointestinal surgery.
- History of HIV, hepatitis B, hepatitis C.
- In need of chronic use of medication, with the exception of birth control medications.
- Currently uses medication for acute illness (other than medications for use of treatment/pain relief of anal fissure).
- Has used, in the last two weeks, drugs that may affect blood coagulation, such as Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin, Clopidogrel, Ticlopidine.
- Is using drug that may affect rectal tone:
Calcium Channel Blocker such as:
- Nifedipine (Osmo-Adlat, Pressolat, Nifedipine -Teva, Nifedilong)
- Amlodipine (Amlow, Norvasc, Amlodipine-Teva)
- Lercadipine (Vasodip)
- Verapamil (Ikacor, Ikapress, Verapress)
- Felodipine (Penedil)
- Diltiazem (Adizem, Dilatam)
Nitrate donors such as:
- Glyceryl Trinitrate (Deponit)
- Isosorbid dinitrate (Isoket, Isolong)
- Isosrbid mononitrate (Monocord, Monolong, Mononit)
- Nitroglycerine (Nitrocine, Nitroderm, Nitrolingual)
- Has upon physical examination a rectal deformation or signs of rectal disease such as bleeding hemorrhoids, fistula. infection or space occupying lesion.
- Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or
- Is employed by RDD Pharma Ltd.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Once daily
Nifedipine 12 mg Once daily
|
|
Experimental: Twice Daily
Nifedipine 12 mg twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To examine the effect of coated Nifedipine suppository on Anal fissure pain as measured by Visual Analog Score
Time Frame: 8 weeks after study initiation
|
8 weeks after study initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To investigate the Safety and tolerability of coated Nifedipine suppositories in Anal Fissure patients .
Time Frame: 8 weeks
|
safety will be assessed by the number of participants with adverse events.
Tolerability will be assessed by the number of participants that discontinue treatment.
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Nir Barak, MD, RDD Pharma Ltd
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
December 11, 2013
First Submitted That Met QC Criteria
December 22, 2013
First Posted (Estimate)
December 30, 2013
Study Record Updates
Last Update Posted (Estimate)
November 17, 2015
Last Update Submitted That Met QC Criteria
November 15, 2015
Last Verified
January 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Intestinal Diseases
- Rectal Diseases
- Anus Diseases
- Fissure in Ano
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Nifedipine
Other Study ID Numbers
- RDD 112
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anal Fissure
-
Zagazig UniversityCompletedChronic Anal FissureEgypt
-
University of NinevehCompleted
-
Mansoura UniversityCompleted
-
Hospital General Universitario ElcheCompletedChronic Anal FissureSpain
-
State Scientific Centre of Coloproctology, Russian...Recruiting
-
Istanbul Medipol University HospitalCompletedAnal Fissure ChronicTurkey
-
Treviso Regional HospitalCompletedAnal Fissure | Anal Fissure ChronicItaly
-
Mansoura UniversityCompleted
-
Hvidovre University HospitalUnknownFocus: Anal Incontinence After Lateral Sphincterotomy for Chronic Anal FissureDenmark
-
KTO Karatay UniversityIstanbul Medipol University HospitalCompletedPRP | Anal Fissure ChronicTurkey
Clinical Trials on Nifedipine 12 mg coated suppositories
-
RDD Pharma LtdCompleted
-
RDD Pharma LtdCompletedAnal Resting PressureIsrael
-
Aphaia Pharma US LLCNovaClin Medical Research Center S.R.L; ACC GmbH Analytical Clinical Concepts; SC Bioclinica... and other collaboratorsCompleted
-
Valenta Pharm JSCCompletedInfluenza, Human | Common Cold | Acute Respiratory InfectionRussian Federation
-
Laboratorios Andromaco S.A.Completed
-
Future University in EgyptCompleted
-
G & W Laboratories Inc.CompletedInternal HemorrhoidsUnited States
-
University of AarhusAarhus University HospitalCompleted
-
Repros Therapeutics Inc.Completed
-
Repros Therapeutics Inc.Completed